CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer
Stopped The sponsor declared the early termination of the study due to poor recruitment of patients.
Conditions
- Metastatic Colorectal Cancer
Interventions
- DRUG: CY-503
- DRUG: Placebo
Sponsor
Cytavis Biopharma GmbH
Collaborators
- [object Object]
- [object Object]
- [object Object]